Computational Biology
Using bioinformatics tools and machine learning to model biological systems, predict protein structures, and analyze genomic data at scale.

Exploring the intersection of biotechnology, bioinformatics, and artificial intelligence to solve complex biological challenges. Current focus on computational biology, drug discovery, and AI-driven research methodologies.
Explore My Research→Combining computational biology, artificial intelligence, and wet-lab research to tackle complex biological challenges and advance precision medicine.
Using bioinformatics tools and machine learning to model biological systems, predict protein structures, and analyze genomic data at scale.
Leveraging AI and structure-based drug design to accelerate compound screening, virtual screening, and therapeutic target identification.
Applying deep learning to large-scale genomic datasets for variant calling, gene annotation, disease association studies, and personalized medicine.
Identifying and validating molecular biomarkers for disease diagnosis, prognosis, and treatment response prediction in clinical applications.
Rational design and directed evolution of proteins with improved function, stability, or novel properties for biotechnology applications.
Integrating multi-omics data to model complex biological networks, pathway analysis, and understand emergent cellular behaviors.
Peer-reviewed research, preprints, and academic contributions across biotechnology, bioinformatics, and computational biology.
We present a novel deep learning pipeline combining transformer architectures with graph neural networks to predict protein secondary and tertiary structures in organisms lacking extensive homology databases. Our approach achieves 94.2% accuracy on held-out test sets and reduces computational overhead by 67% compared to existing methods.
10.1038/s43588-024-00642-xThis study demonstrates a synergistic approach combining high-throughput CRISPR screening with advanced bioinformatic analysis to identify novel therapeutic targets in cancer cell lines. We identified 47 candidate genes with validated off-target effects and ranked them by biological relevance using machine learning-enhanced pathway analysis.
10.1093/gbe/evs123We developed a random forest classifier combined with ensemble methods to taxonomically classify 16S rRNA sequences from diverse environmental samples. Our model outperformed traditional BLAST-based methods with 98.1% accuracy and reduced false positive rates by 56% in simulated low-abundance scenarios.
10.1007/s00253-023-12456-xA computational drug repurposing pipeline integrating protein-protein interaction networks, molecular docking simulations, and systems pharmacology to identify existing drugs with potential SARS-CoV-2 activity. We prioritized 12 compounds for experimental validation based on binding affinity, safety profiles, and clinical availability.
10.1101/2023.04.15.537001Multi-omics integration of longitudinal transcriptomic data from 450 individuals identified 63 gene expression signatures associated with cognitive decline trajectories. Machine learning models trained on these signatures achieved 88% sensitivity in predicting progression to mild cognitive impairment within 18 months.
10.1038/s41380-023-02000-zWe evaluated quantum-classical hybrid algorithms for molecular docking on NISQ devices, demonstrating comparable accuracy to classical methods for small-molecule-protein interactions while exhibiting potential for 3-4x speedup on future fault-tolerant quantum computers.
10.1002/jcc.27001I am committed to advancing the boundaries of biotechnology and AI through ambitious, focused research initiatives that address real-world healthcare challenges and drive innovation in personalized medicine.
I am actively seeking collaborations with research groups, industry partners, and innovators working at the intersection of biotech and AI. Whether you share research interests or have exciting opportunities, I'd love to connect.
Propose a CollaborationA collection of my lab experiences, research focus areas, key projects, and the mentors and institutions that shaped my scientific approach.
Developing machine learning models for rare disease diagnosis using genomic and clinical data integration.
Applying transformers and graph neural networks to clinical time-series data for patient outcome prediction.
Computational design of synthetic biological circuits and optimization of gene regulatory networks.
Bioinformatics pipeline development for high-throughput genomic analysis and variant annotation.
Research is not just about publications or accolades. It's about advancing human knowledge, solving real-world problems, and building a foundation for the next generation of scientists.
Throughout my journey in computational biology and bioinformatics, I've come to believe that excellent research is built on a few core principles. These aren't just abstract ideals—they guide every decision I make, from project selection to manuscript preparation to collaboration.
Reproducibility isn't just good practice—it's the foundation of scientific integrity. Every computational analysis, every figure, every conclusion should be independently verifiable. This means rigorous documentation, open-source code, and transparent methods.
I'm passionate about making complex biological data accessible and interpretable for the broader scientific community. Too often, innovative computational methods remain trapped in academic papers or locked behind proprietary software. I believe in developing tools that researchers actually use, with documentation they can understand, and results they can trust.
Science thrives at intersections. The breakthroughs I'm most excited about happen when computational biologists collaborate with wet-lab researchers, when bioinformaticians partner with clinicians, when AI practitioners engage with domain experts.
My work across biotechnology, bioinformatics, and artificial intelligence has taught me thatthe most impactful solutions are rarely found in isolation. A robust statistical model means nothing without biological grounding. A sophisticated deep-learning architecture fails if it doesn't address real clinical challenges. I actively seek collaborations that push me outside my comfort zone and bring diverse perspectives to the research table.
Research must ultimately serve humanity. Whether through advancing precision medicine, improving drug discovery timelines, or enabling more equitable healthcare, the end goal is tangible impact on human health and wellbeing.
I'm committed to responsible and ethical research practices. This includes careful consideration of data privacy, informed consent, potential bias in AI models, and equitable access to research findings. As AI and bioinformatics shape the future of healthcare, we have a responsibility to build systems that are fair, interpretable, and beneficial for all populations—not just the privileged few.
I champion open science—sharing data, code, and findings freely. The scientific enterprise advances faster when we remove barriers to knowledge.
High standards in methodology, analysis, and reporting. Peer review strengthens research, and I welcome rigorous critique.
Research communities thrive through knowledge transfer. I'm committed to mentoring the next generation of scientists and engineers.
This philosophy drives my choice of research problems, my collaboration strategies, and how I contribute to the scientific community. It's not a destination but an ongoing commitment to grow, learn, and push the boundaries of what's possible in computational biology and AI-driven discovery.
Whether you're exploring research opportunities, seeking a collaborator, or interested in discussing biotech and AI applications in healthcare, I'd love to connect. Reach out to discuss potential projects or exchange ideas.
No comments yet. Be the first!